Chapter 3
Industry Innovation
2023 U.S. Life Sciences Outlook
3 Minute Read
Looking for a PDF of this content?
Innovation & New Products Driving Industry Expansion
Clinical studies are a vital part of the life sciences company life cycle. Phase 2 and 3 trials in particular are a tipping point for companies as they determine the effectiveness of the drug/product being developed. Results from these studies help determine if a company will expand or contract, especially with startups.
Figure 15: Number of New Phase 2 & Phase 3 U.S. Clinical Trials
Source: ClinicalTrials.gov, CBRE Research.
Note: Includes all interventional studies (clinical trials) except those that are withdrawn, suspended or terminated. Includes trials by date first posted to database with a start date on or after 1/1/2012.
The Food & Drug Administration (FDA) approved 37 novel drugs in 2022, down from 50 in 2021 and the previous 10-year average of 43. As of the end of February 2023, seven new drugs have been approved, on par with last year’s approval rate at this time. Despite increasingly onerous regulations for drug approvals, the majority of the new drugs approved last year used one of the four expedited processes for FDA approval. While approvals are down, new drug applications are up.
Figure 16: Food & Drug Administration Novel Drug Approvals by Year
Source: U.S. Food & Drug Administration, 2022.
Related Service
- Property Type
Life Sciences
We provide the life sciences industry solutions that maximize facility and investment performance across labs, manufacturing space and critical enviro...
Related Insights
- Article | Evolving Workforces
Integrated lab and extended reality solutions: the augmented future of lab asset management with CBRE
February 21, 2023 5 Minute Read
CBRE has pioneered the use of direct collaboration with original equipment manufacturers (OEMs) and on-site troubleshooting, driving forwards faster installatio...
- Chapter | Intelligent Investment
U.S. Real Estate Market Outlook 2023: Life Sciences
December 13, 2022 5 Minute Read
In 2023, Pandemic-fueled demand and capital infusion will give way to more normal market conditions, with better opportunities for occupiers.
- Brief | Intelligent Investment
Lab/R&D Space Market Remains Strong Despite H1 2022 Drop in Life Sciences Funding
August 3, 2022 3 Minute Read
After peaking in 2021, life sciences funding has plunged this year due to market uncertainty.
Contacts
Matthew Gardner
Americas Advisory Leader Life Sciences
Eric Stavriotis
Vice Chairman, Advisory & Transaction Services | Location Incentives
Insights in Your Inbox
Stay up to date on relevant trends and the latest research.